期刊文献+

顺铂联合依托泊苷或伊立替康及拓扑替康一线治疗小细胞肺癌的比较研究 被引量:9

Cisplation combined with etoposide irinotecan and topotecan respectively forpatients with small cell lung cancer as first-line treatment
原文传递
导出
摘要 目的:比较依托泊苷(Vp-16)、伊立替康(CPT-11)和拓扑替康(TPT)分别联合顺铂(DDP)组成的EP、IP和TP方案一线治疗小细胞肺癌(SCLC)的近期疗效及毒副作用。方法:81例SCLC患者采用随机数字表法分为3组,每组27例,分别接受EP、IP或TP方案化疗>3个周期,评价疗效和毒副作用。结果:EP组患者近期有效率(RR)为66.67%(18/27),IP组为74.07%(20/27),TP组为62.96%(17/27)。EP和IP组比较差异无统计学意义,χ2=0.089,P=0.766;EP和TP组比较差异无统计学意义,χ2=0.000,P=1.000;IP和TP组比较差异无统计学意义,χ2=0.343,P=0.559。EP组疾病控制率(DCR)为88.89%(24/27),IP组为88.89%(24/27),TP组为85.19%(23/27),差异无统计学意义,χ2=0.000,P=1.000。TP组Ⅲ~Ⅳ度白细胞下降发生率明显高于IP组,χ2=5.494,P=0.018;TP组Ⅲ~Ⅳ度血小板下降发生率明显高于EP组,χ2=3.668,P=0.050;IP组Ⅲ~Ⅳ度迟发性腹泻发生率明显高于其他两组,χ2=4.688,P=0.023。结论:IP和TP方案一线治疗SCLC与EP方案疗效相当,IP方案有相对较高的迟发性腹泻发生,TP方案有较高的血液毒性,这些毒副作用通过对症处理可控制。 OBJECTIVE:To compare the efficacy and toxicity of etoposide plus cisplation (EP) regiment,irinotecan plus cisplation (IP) regiment and topotecan plus cisplation (TP) regiment in first-line treatment of small cell lung cancer (SCLC). METHODS:Totally 81 patients of SCLC were divided equally by digital random table method,and treated with EP regiment,IP regiment and TP regiment. All patients were given more than three chemotherapy cycles. The therapeu- tic effect and toxicity were evaluated after the treatment. RESULTS: The overall response rates (RR) were 66.67 (18/27) ,74.07%(20/27) and 62.96% (17/27). There were no significant differences among the three groups (EP vs IP, ;(2=0.089,P=0.766;EP vs TP,X^2=0.000,P=1.000;IP vs TP,;(2=0.343,P=0.559). The disease control rates (DCR) were 88.89 % (24/27),88.89 % (24/27) and 85.19% (23/27). There were no significant differences for the three groups (X^2 = 0. 000, P= 1. 000). Ⅲ-Ⅳ grade leucopenia for that of TP regimen was higher than IP regimen (X^2 = 5. 494, P = 0. 018). Ⅲ-Ⅳ grade thrombocytopenia for TP regimen was higher than that of EP regimen (X^2 = 3. 668, P = 0. 050).Ⅲ-Ⅳ grade tardily diarrhea for IP regimen was higher than that for the other two groups (X^2 = 4. 688,P= 0. 023). CON- CLUSIONS.. IP regimen and TP regimen in the first-line treatment of SCLC have good clinical efficancy. IP regiment has higher diarrhea incidence and TP regiment has higher hematological toxicities, and these side effects are tolerable by symp- tomatic treatment.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第10期782-785,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 伊立替康 拓扑替康 小细胞肺癌 化疗 irinotecan topotecan SCLC chemotherapy
  • 相关文献

参考文献18

  • 1Ou SH,Ziogas A,Zell lA. Prognostic factors for survival in ex?tensive stage small cell lung cancer (ED-SCLC) : the importance of smoking history, socioeconomic and marital statuses, and eth?nicity[J].J Thorac Oncol,2009 ,4(1) :37-43.
  • 2Jiang L, Yang KH,Guan QL,et a1. Cisplatin plus etoposide ver?sus other platin-based regimens for patients with extensive small cell lung cancer: a systematic review and meta analysis of ran?domized controlled trials[J]. Intern MedJ, 2012, 25. doi , 10. l11l/j. 1445-5994.2012. 02821. x.[Epub ahead of print].
  • 3Spigel DR,Greco FA,Rubin MS,et a1. Phase II study of main?tenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer[J]. Lung Cancer,2012 ,77(2) :359-364.
  • 4Hosomi Y,Shibuya M, Niho S, et a1. Phase II study of topote?can with cisplatin inJapanese patients with small cell lung cancer[J]. Anticancer Res,2011 ,31(10) :3449-3455.
  • 5Rossi A, Martelli 0, Di Maio M, et a1. Treatment of patients with small-cell lung cancer: From meta-analyses to clinical practice[J]. Cancer Treat Rev, 2 doispii, 50305-7372(12)00191-0. 10.1016/j. ctrv. 2012. 09. 006.[Epub ahead of print].
  • 6Schmittel A. Second-line therapy for small-cell lung cancer[J]. Expert Rev Anticancer Ther,.2011,11(4) :631-637.
  • 7Zhou Y , Gwadry FG, Reinhold WC, et al. Transcriptional regula?tion of mitotic genes by camptcthecin-induced DNA damage: mi?croarray analysis of dose-and time- dependent effects[J]. Cancer Res,2002,62(6):1688-1695.
  • 8Alagoz M,Gilbert DC, El-Khamisy S, et al. DNA repair and re?sistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets[J]. Curr Med Chern, 2012,19 (23): 3874-3885.
  • 9Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cispla?tin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Eng[J Med,2002,346(Z) :85-91.
  • 10HannaN,BunnPAJr,LangerC,etal. Randomized phase ill tri?al comparing irinotecan/ cisp latin with etoposide/ cisp latin in pa?tients with previously untreated extensive-stage disease small?cell lung cancer[J].J Clin Oncol,2006 ,24(13) :2038-2043.

二级参考文献50

  • 1刘炬,张雪梅,张湘茹,袁芃,徐兵河,林东昕.ERCC6 C6530G单核苷酸多态与局限期小细胞肺癌患者生存相关[J].中国癌症杂志,2006,16(11):943-947. 被引量:7
  • 2吴一龙,蒋国梁,陆舜.2007中国肺癌临床指南[M].北京:人民卫生出版社,2007:1-10.
  • 3Kelly H, Goldberg R M. Systemic therapy for metastatic colorectal cancer: current options, current evident[J]. J Clin Oncol, 2005, 23(20): 4553-4560.
  • 4Simon M, Argiris A, Murren J R. Progress in the therapy of small cell lung caneer[J]. Crit Reu Oncol Hematol, 2004, 49(2): 119.
  • 5Socinski M A, Weissman C, Hart L L, et al. Randomized phase Ⅱ trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer[J]. J Clin Oncol, 2006, 24(30),4840.
  • 6O'Reilly S, Rowinsky E K. The Clinical status of irinotecon (CPT- 11), a novel water soluble eamptothecin analogue[J]. Crit Rev Oncol/Hematol, 1996, 24:47.
  • 7Hirose T, Horichi N, Ohmori T, et al. Phase Ⅱ study of irinoteean and carboplatin in patients with the refractory or relapsed small cell lung cacer[J]. Lung Cancer,2003, 40(3):333-338.
  • 8Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small- cell lung cancer[J]. N Engl J Med,2002, 346(2):85-91.
  • 9Ichiki M, Gohara R, Rikimaru T, et al. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small-cell lung cancer: a phase Ⅱ study[J]. Chemotherapy, 2003, 49(4):200-205.
  • 10Dally H, EdIer L, Jager B, et al. The CYP3A41B allele increases risk for small cell lung cancer: effect of gender and smoking dose[J]. Cancer Epidemiol Biomarkers Prey, 2007, 16 (2) : 214- 222.

共引文献11

同被引文献84

  • 1曹子昂.2014第一版NCCN小细胞肺癌治疗指南解读[J].中国医学前沿杂志(电子版),2013,5(12):79-81. 被引量:24
  • 2郑筱祥,杨勇,叶剑锋,李小龙,尤金花,田守生.东阿阿胶的升白作用及机制研究[J].中国现代应用药学,2005,22(2):102-105. 被引量:47
  • 3张中冕,刘萍,田薇薇,杨家梅,王健,韩娜.EP方案联合放疗序惯拓扑替康治疗小细胞肺癌53例[J].第四军医大学学报,2005,26(13):1229-1229. 被引量:1
  • 4Noda K, Nishiwaki Y,Kawahara M, et al. Irinotecan plus cispla- tin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Engl J Med,2002,346(2) :85-91.
  • 5Nakamura Y,Soda H,Oka M,et al. Randomized phase Ⅱ trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1- 6 and UGT1A1 with severe neutropenia [J]. J Thorac 0ncol,2011,6(1):121-127.
  • 6Tie J,Pan Y,Zhao L,et al. miR-218 inhibits invasion and metas- tasis of gastric cancer by targeting the Robol receptor[J]. Plos Genet,2010,6(3) :e1000879.
  • 7Hirose K, Kozu C, Yamashita K, et al. Correlation between plasma concentration ratios of SN-38 gluscuronide and SN-38 and neutrope- nia induction in patients with colorectal cancer and wild-type UGT1A1 gene [J]. Oncol Lett,2012,3(3) :694-698.
  • 8Martinez-Balibrea E,Abad A,Mavtinez-Cardfius A,et al. UGT1A1 and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with firstline irinotecan and fluorouracil combination therapy [J]. Br J Cancer,2010,103(4) :581-589.
  • 9Davidson MR, Larsen JE, Yang IA, et al. MicroRNA-218 is dele- ted and down regulated in lung squamous cell carcinoma[J]. Plos One,2010,5(9) :e12560.
  • 10Sugiyama T, Hirose T, Kusumoto S, et al. The UGT1A1 * 28 geno- type and the toxicity of low-dose Irinotecan in patients with advanced lung cancer[J]. Oncol Res, 2010,18 (7) : 337-342.

引证文献9

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部